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rion diseases are characterized by degeneration of central nervous tissue associated with the replication of a transmissible agent, a prion. 1 Prions are mainly composed of an abnormal, partially protease-resistant conformer (PrP Sc ) of a cellular protein (PrP C ). 2 Although tissue damage occurs only in the central nervous system, the accumulation of PrP Sc and prion infectivity are not necessarily confined to neural tissue in all prion diseases. In scrapie in sheep, chronic wasting disease in deer, and numerous animal models of prion diseases, prions invade the lymphoreticular system. 3 PrP Sc has also been reported in the skeletal muscle of mice with experimentally induced prion disease. 4 The most common prion disease in humans is Creutzfeldt-Jakob disease, which has been classified as sporadic, familial, iatrogenic, or variant. The causation of sporadic Creutzfeldt-Jakob disease is unclear, whereas biochemical, histopathological, and epidemiologic evidence suggests that the variant form results from the transmission of bovine spongiform encephalopathy prions to humans. 5, 6 PrP Sc accumulates in tonsils 7 and other lymphoreticular organs 8 of patients with variant CreutzfeldtJakob disease, 9 whereas the sporadic form of the disease is not thought to target the lymphoreticular system. 10 The allegedly unique involvement of the lymphoreticular system in variant CreutzfeldtJakob disease serves as a diagnostic criterion to distinguish variant from sporadic Creutzfeldt-Jakob disease and is one of the principal pieces of evidence that these forms represent two distinct disease entities. 6 Refinements in the sensitivity of the methods of detection 11 prompted us to reinvestigate the distribution of PrP Sc in humans with sporadic Creutzfeldt-Jakob disease.
collection of samples
We collected central nervous system, spleen, and muscle samples at autopsy from a cohort of Swiss patients who died between 1996 and 2002: 36 patients with prion disease (36 brain specimens, 32 muscle specimens, and 28 spleen specimens), 10 with Alzheimer's disease (10 muscle and 8 spleen samples), and 9 patients without neurologic disorders (9 muscle and 9 spleen samples). The utmost care was taken to avoid contamination of extraneural samples with central nervous system tissue. All tissues were processed according to established guidelines regarding safety and ethics.
detection of p r p Sc in extraneural tissues
All procedures were carried out in biosafety level 3 facilities with strict adherence to safety guidelines. The method of precipitation with the use of sodium phosphotungstic acid was adapted from published protocols. 8 We prepared 10 percent tissue homogenates (weight per volume) in 2 percent sarkosyl in sterile phosphate-buffered saline using a RiboLyser (Hybaid). Cellular debris was removed by centrifugation at 80¬ g for one minute in a microcentrifuge. Occasional residual debris was removed by additional centrifugation at 2700¬ g for five minutes. Supernatants (500 µl) were mixed with equal volumes of 2 percent sarkosyl in phosphate-buffered saline and incubated for 10 minutes at 37°C. Benzonase (Benzon nuclease, Merck) and magnesium chloride were added (final concentration, 50 units per milliliter and 1 mmol per liter, respectively), and the mixture was incubated under constant agitation for 30 minutes at 37°C.
Samples were adjusted to a final concentration of 0.3 percent phosphotungstate, incubated at 37°C for 30 minutes under constant agitation, and centrifuged at 15,800¬ g for 30 minutes in a microcentrifuge. The pellets were resuspended in 20 µl of phosphate-buffered saline with 0.1 percent sarkosyl. Samples were adjusted to a final concentration of 20 µg of proteinase K per milliliter and incubated at 37°C for 30 minutes. Digestion was terminated by the addition of protease inhibitors (Complete protease inhibitor cocktail, Boehringer Mannheim). Samples were boiled in loading buffer (125 mM TRIS sodium chloride, 4 percent sodium dodecyl sulfate, 20 percent glycerol, and 0.02 percent bromophenol blue), subjected to electrophoresis in 12 percent TRIS-glycine gels, and blotted on nitrocellulose membranes. Membranes were blocked with 5 percent Topblock (Jura) in phosphate-buffered saline with 0.05 percent Tween and then incubated overnight with a monoclonal antibody against PrP (3F4; dilution 1:5000). 12 The samples were then incubated with an alkaline-phosphatase-conjugated secondary antibody (1:20,000) and examined with use of 2-chlor-5-(4-methoxyspiro{1,2-dioxetan-3,2'-(5'-chlor) tricycl [3.3.1.13,7] decan}-4-yl)-1-phenylphosphate dinatrium salt chemiluminescent substrate (Amersham) and a VersaDoc digital imager (model 5000, p methods Bio-Rad). Each blot included appropriate positive and negative controls (10 µg or 100 µg of brain homogenate from a patient with sporadic CreutzfeldtJakob disease or a patient without a prion disease added to 50 mg of muscle or spleen specimen from a patient without a prion disease). All analyses were carried out and all but six samples were examined at least twice by independent investigators. Samples were deemed positive if proteinase K-resistant diglycosylated, monoglycosylated, and unglycosylated bands with electrophoretic motility indicative of PrP Sc were unambiguously identified.
detection of p r p Sc in neural tissues
Western blot analysis was carried out as described previously. 13 PrP glycoforms were quantified with use of a Kodak image station (model 440) or a VersaDoc digital imager (model 5000), and patients were typed according to the size of the protease-resistant core PrP fragment 14 and the prevalence of glycoforms. 15, 16 genetic analysis Genomic DNA was extracted from frozen tissues. Polymerase chain reaction and analysis of the entire coding region of the prion protein gene ( PRNP ) were performed with use of standard techniques and software (SeqScape, Applied Biosystems). In addition, codon 129 polymorphisms were identified by restriction-fragment-length polymorphism analysis. 17 
histologic analysis
Tissue was fixed with 4 percent buffered formalin, inactivated by exposure to 98 percent formic acid for one hour, and embedded in paraffin. Sections (3 µm) were subjected to conventional staining and to immunostaining for glial fibrillary acid protein (Dako) and PrP (monoclonal antibody 3F4) after hydrolytic autoclaving.
We analyzed a total of 45 spleen specimens and 51 skeletal-muscle samples from 36 patients with histopathologically, biochemically, and genetically confirmed sporadic Creutzfeldt-Jakob disease (mean [ ± SD] age, 66.8 ± 8.7 years; 20 men and 16 women); 10 patients with Alzheimer's disease (mean age, 76.2 ± 4.6 years; 6 men and 4 women); and 9 patients without neurologic disease (mean age, 59 ± 19.2 years; 5 men and 4 women). The age distribution, sex ratio, and duration of disease (mean, 5.0 ± 4.6 months) of the cohort of patients with sporadic Creutzfeldt-Jakob disease did not differ significantly from those in published series. 18 accumulation of p r p Sc in spleen and skeletal muscle Western blot analysis of protease-resistant prion protein after phosphotungstate precipitation showed PrP Sc in 10 of 28 spleen samples and in 8 of 32 skeletal-muscle samples from the patients with sporadic Creutzfeldt-Jakob disease (Fig. 1) . Three patients had PrP Sc in both spleen and muscle (Table 1). Assays were repeated with independently homogenized tissue fragments: three spleen and three muscle samples always tested positive, whereas others yielded variable results (Table 1) , possibly because of inhomogeneous peripheral distribution of PrP Sc , as described previously. 4, 19 Control samples of spleen and muscle were assessed in parallel: none of them contained PrP Sc (data not shown). Patients with PrP Sc in spleen and patients without PrP Sc in spleen did not differ significantly with respect to age (Table 2) . However, patients with PrP Sc only in spleen or in spleen or muscle or both had significantly longer intervals between the onset of clinical symptoms and death than did patients without extraneural PrP Sc . Patients with PrP Sc in muscle tended to be younger at death than patients without PrP Sc in muscle ( Table 2) . None of the subgroups differed significantly with respect to the ratio of men to women.
One patient with splenic PrP Sc had received a cadaveric dura mater transplant more than 22 years before the onset of dementia. This case was deemed unlikely to represent iatrogenic transmission, since the incubation period would be longer than that in any other documented case of dura mater-associated transmission. 20 
genetic analysis of prnp
We sequenced the entire open reading frame of PRNP from all patients with extraneural PrP Sc and found no disease-associated mutations. The common methionine-valine polymorphism at codon 129 was analyzed in all 10 patients with splenic PrP Sc and all 8 patients with muscle PrP Sc as well as in 15 patients without splenic PrP Sc and 21 patients without muscle PrP Sc . We observed a tendency toward overrepresentation of heterozygosity for methionine and valine and homozygosity for valine among patients with splenic PrP Sc , whereas the maresults jority of patients with muscle PrP Sc were homozygous for methionine (Table 2) .
histologic and biochemical analyses
Typical histopathological features of sporadic Creutzfeldt-Jakob disease, consisting of spongiform changes, neuronal loss, and gliosis, were present in all patients (Fig. 2) . The electrophoretic mobility of unglycosylated, protease-digested PrP Sc (also called the core fragment size, which can be 21 kD for type 1 or 19 kD for type 2) 14 allows for the stratification of Creutzfeldt-Jakob disease into subgroups with specific clinical features, which may be caused by different prion strains. 6 A finer degree of stratification is attained by including information on the codon 129 genotype and patterns of cerebral deposition of PrP Sc ; accordingly, we assigned each patient in our series to one of seven proposed groups. 18 This analysis indicated an overrepresentation of uncommon variants of sporadic Creutzfeldt-Jakob disease such as MM2C (homozygous for methionine, type 2, with cortical deposition) and MV2 (heterozygous, type 2) in patients with extraneural PrP Sc ( Table 2 ), suggesting that peripheral deposition of PrP Sc may identify a biochemically or genetically unique subgroup of patients. * Up to four individual fragments of each organ were independently homogenized, subjected to phosphotungstate precipitation, and analyzed by Western blotting. Variability in detection may be due to inhomogeneous distribution of PrP Sc in extraneural organs. ND denotes not done. Lanes 1 and 2 show Western blot (total protein) analysis of 50 µg of brain homogenate from a patient without Creutzfeldt-Jakob disease. Lanes 3 and 4 show brain homogenate from a patient with sporadic Creutzfeldt-Jakob disease diluted with spleen homogenate from a patient without a prion disease (control); lanes 5 and 6 brain homogenate from a control diluted with spleen homogenate from a control; lanes 7 and 8 spleen homogenate from a patient with sporadic Creutzfeldt-Jakob disease; and lanes 9, 10, 11, 12, and 13 muscle homogenate from a patient with sporadic Creutzfeldt-Jakob disease. PrP Sc is present in two samples (lanes 7 and 10). Lanes 2, 4, and 6 through 13 show results after proteinase K digestion. Quantification of the relative prevalence of diglycosylated, monoglycosylated, and unglycosylated PrP Sc is a further instrument for the biochemical characterization of PrP Sc , which allows one to discriminate sporadic from variant CreutzfeldtJakob disease. 16 This analysis did not uncover any unorthodox PrP Sc glycotypes in patients with peripheral PrP Sc (Fig. 3) : the distribution of brain glycotypes in patients with peripheral PrP Sc was similar to that in other cohorts of patients with sporadic Creutzfeldt-Jakob disease. 13 
distribution of p r p Sc in skeletal-muscle groups
Earlier studies in mice have shown that the PrP Sc content may vary among muscle groups. 4 In our series, the presence of PrP Sc was not limited to specific muscle groups: PrP Sc was found in four samples of pectoral muscle, two samples of psoas muscle, and two samples of intercostal muscle. It was absent in 10 pectoral-muscle specimens, 5 psoasmuscle specimens, 2 biceps-muscle specimens, and 4 intercostal-muscle specimens. In three patients without extraneural PrP Sc , no information on the anatomical origin of muscle samples could be obtained.
quantification of p r p Sc in extraneural organs
In order to estimate the relative concentration of PrP Sc in extraneural organs, we compared the intensity of proteinase K-digested Western blot signals with calibration curves obtained by diluting brain homogenate from a patient with Creutzfeldt-Jakob disease with muscle or spleen homogenate from a patient without a prion disease. Despite considerable variations in individual spleen and muscle specimens, the signal intensity of peripheral PrP Sc was generally similar to that obtained when 10 µg of brain homogenate from a patient with sporadic Creutzfeldt-Jakob disease was diluted with 50 mg of spleen or muscle from a patient without a prion disease (Fig. 1) . Therefore, we estimate that the levels of PrP Sc in extraneural organs are lower by a factor of approximately 1¬10 ¡4 than those typically found in the central nervous system of patients with sporadic Creutzfeldt-Jakob disease.
Previous studies did not detect PrP Sc in the tonsils, spleen, lymph nodes, 10 or appendix of patients with sporadic Creutzfeldt-Jakob disease. 21 How- ever, after a systematic search for PrP Sc in extraneural organs of patients referred to the Swiss National Reference Center for Prion Diseases, we found that extraneural deposits of PrP Sc are much more frequent in patients with sporadic Creutzfeldt-Jakob disease than previously thought. There may be several reasons why this fact was not previously recognized. First, our series of patients is much larger than previous ones. Second, repeated homogenization of distinct fragments of extraneural organs identified substantial variations in the PrP Sc content of these tissues. Generic problems related to the technical reproducibility of our results are unlikely to account for this variation, since control samples consisting of brain homogenate from a patient with sporadic Creutzfeldt-Jakob disease diluted with muscle or spleen homogenate from a patient without a prion disease did not have such variations (data not shown). Instead, the presence of variability suggests that the distribution of PrP Sc is not homogeneous in single muscle fibers and single splenic germinal centers. This finding parallels the finding that prion infectivity titers vary in spleen 22 and muscle 4 samples from experimentally infected mice.
Third, PrP Sc levels in spleen and muscle were lower than those in brain by a factor of 1¬10 ¡4 : extraneural PrP Sc was never detectable by plain Western blot analysis (data not shown) and could be visualized only after sodium phosphotungstic acid precipitation, an approach that increases the sensitivity of Western blot analysis by three orders of magnitude by preferentially precipitating PrP Sc from tissue homogenates. 8, 11 Although this method is not suitable for use with very small biopsy specimens (less than 100 mg), it is ideal for situations in which sample size is not a limiting factor.
Previous studies suggested the presence of abnormal PrP in the skeletal muscle of patients with inclusion-body myositis. 23 However, this may represent denervation-dependent up-regulation of PrP C transcription. 24 In one patient with coincident sporadic Creutzfeldt-Jakob disease and inclusion-body myositis, we found PrP Sc levels that were 10 3 times as high as the levels in our study cohort, possibly because the overexpression of PrP C in muscle facilitates the deposition of PrP Sc (Kovacs G: personal communication).
Does the presence of peripheral PrP Sc correlate with any specific genetic, biochemical, or clinical The relative ratios of PrP Sc glycoforms are different in sporadic and variant Creutzfeldt-Jakob disease. Glycotype analysis failed to reveal features specific to patients with peripheral PrP Sc , and none of them had the glycoform distribution associated with variant Creutzfeldt-Jakob disease. Patients with splenic PrP Sc had significantly longer durations of disease than did those without splenic PrP Sc . Assuming that prions arise primarily in the central nervous system of these patients, one might speculate that protracted disease increases the likelihood of spillover of cerebral PrP Sc to extraneural areas. The triangular plot correlates the intensities of the diglycosylated (upper), monoglycosylated (middle), and unglycosylated (lower) bands of PrP Sc . Study patients with sporadic Creutzfeldt-Jakob disease and PrP Sc in spleen, muscle, or both; study patients with sporadic Creutzfeldt-Jakob disease but no PrP Sc in spleen or muscle; and British control patients with sporadic Creutzfeldt-Jakob disease (black, dark gray, and light gray boxes) cluster in the same area of the plot. Instead, control patients with variant Creutzfeldt-Jakob disease (white square 13 ) are segregated in a distinct region of the plot. Although the amount of PrP Sc found in spleen and muscle samples from patients with sporadic Creutzfeldt-Jakob disease was much lower than levels in lymphoid organs of patients with variant Creutzfeldt-Jakob disease, 7 and the infectivity of prions from these tissues awaits verification, our findings arouse concern about the possibility of iatrogenic transmission of sporadic Creutzfeldt-Jakob disease. Brown et al. reported that extraneural tissues of patients with spongiform encephalopathy (including hereditary forms and kuru) occasionally transmitted disease when inoculated into nonhuman primates. 27 Infectivity was detected in 2 of 4 lung-tissue samples, 4 of 35 liver specimens, 5 of 28 kidney specimens, 3 of 31 spleen samples, and 3 of 15 lymph-node samples. 27 Five attempts to transmit the disease through the inoculation of skeletal muscle were not successful, possibly because the sample size was insufficient, because the infectivity of the samples was not uniform, or because transmission from human to nonhuman primates is not always highly efficient.
The causation of sporadic Creutzfeldt-Jakob disease is unknown. Some allegedly sporadic cases may in reality have an iatrogenic origin, and surgery of any kind was found to constitute a mild risk factor for sporadic Creutzfeldt-Jakob disease. 28 Extensive epidemiologic surveys did not substantiate any risk of blood-borne transmission, 29 suggesting that the presence of PrP Sc in lymphoid organs whose cellular constituents migrate to and from blood may not lead to substantial contamination of blood donations by prions.
Many patients with sporadic Creutzfeldt-Jakob disease are subjected to extensive neurologic examinations in the prodromal stages, often including electromyography and muscle biopsies. The finding that PrP Sc is prevalent in skeletal muscle reinforces calls for the use of single-use needle electrodes and of special protocols for the sterilization of surgical instruments used for muscle biopsies.
Our results suggest that muscle and lymph-node biopsies can be used as diagnostic procedures for sporadic Creutzfeldt-Jakob disease. Because of the unambiguous and extremely specific nature of the immunochemical detection of PrP Sc , any positive results would firmly establish the diagnosis of Creutzfeldt-Jakob disease without the need for more invasive procedures. However, the diagnostic sensitivity of the detection of PrP Sc in muscle-biopsy specimens is likely to be low, since less than one third of our patients were positive for PrP Sc in muscle. We did not detect PrP Sc in one muscle-biopsy specimen obtained because of suspected vasculitis 10 weeks before death in a patient with CreutzfeldtJakob disease (data not shown). The sensitivity of prion detection is likely to improve soon, in view of the considerable refinements in the technique that are being reported. 30 In contrast to previous reports, our study focused on a homogeneous, narrowly defined group of patients. All the patients had died of sporadic Creutzfeldt-Jakob disease in Switzerland between 1996 and 2002. On the other hand, there has been an alarming increase in the incidence of CreutzfeldtJakob disease in Switzerland. 13 Although the causes of this epidemiologic shift are not clear, the etiologic process of sporadic Creutzfeldt-Jakob disease in our cohort may differ from that in cohorts in other countries. It will therefore be important to extend the present study to additional countries, in order to determine whether our observations apply to all cases of sporadic Creutzfeldt-Jakob disease.
